HomeDolutegravir Sodium And LamivudineDolutegravir Sodium And Lamivudine + Dalfampridine

Does Dolutegravir Sodium And Lamivudine Interact with Dalfampridine?

Dolutegravir Sodium And Lamivudine and Dalfampridine have a major drug interaction according to U.S. FDA drug labeling data. Dolutegravir inhibits renal OCT2 and MATE1 transporters, which may increase plasma concentrations of dalfampridine. The mechanism involves inhibition of oct2 and mate1 transporters. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.

Severity
Major
Dolutegravir Sodium And Lamivudine Class
Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Dalfampridine Class
Potassium Channel Blocker
Management
Close medical supervision required
Data Source
U.S. FDA via OpenFDA

How This Interaction Works

The interaction between Dolutegravir Sodium And Lamivudine and Dalfampridine occurs because inhibition of oct2 and mate1 transporters. Clinically, this means dolutegravir inhibits renal oct2 and mate1 transporters, which may increase plasma concentrations of dalfampridine. This is classified as a major interaction, meaning it could cause serious harm if not properly managed. Your healthcare provider may need to adjust dosages, substitute one medication, or increase monitoring frequency.

What To Tell Your Doctor or Pharmacist

If you are taking Dolutegravir Sodium And Lamivudine and your doctor is considering prescribing Dalfampridine (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Ask how frequently you should be monitored while these are co-prescribed
  • Ask whether any dosage adjustments are needed
  • Never stop or change either medication without first consulting your healthcare provider
💊 Dolutegravir Sodium And Lamivudine(Dovato)+💊 Dalfampridine(Dalfampridine)

Severity & Interaction Details

⚠️
major
Use with caution — major interaction
Serious risk of clinically significant harm. Generally avoid; if used, monitor closely.
Severity scale
MinorContra
On record
Yes
Drug A class
Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Drug B class
Potassium Channel Blocker
Source
NLP:dolutegravir sodium and lamivudine

What this means in plain English

Dolutegravir inhibits renal OCT2 and MATE1 transporters, which may increase plasma concentrations of dalfampridine.

What the FDA label says

"Inhibition of OCT2 and MATE1 transporters"

📖 Source: NLP:dolutegravir sodium and lamivudine

Share this result:XFacebookWhatsAppReddit
Add more drugs
Check Dolutegravir Sodium And Lamivudine and Dalfampridine against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.